Էստոնիա - էստոներեն - Ravimiamet

septodont - artikaiin+epinefriin (adrenaliin) - süstelahus kolbampullis - 40mg+0,01mg 1ml 1.7ml 50tk

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

pfizer europe ma eeig - tofacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

abbvie deutschland gmbh & co. kg - upadacitinib - artriit, reumatoidartriit - immunosupressandid - rheumatoid arthritisrinvoq is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (dmards). rinvoq may be used as monotherapy or in combination with methotrexate. psoriatic arthritisrinvoq is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more dmards. rinvoq may be used as monotherapy or in combination with methotrexate. axial spondyloarthritisnon-radiographic axial spondyloarthritis (nr-axspa)rinvoq is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri), who have responded inadequately to nonsteroidal anti-inflammatory drugs (nsaids). ankylosing spondylitis (as, radiographic axial spondyloarthritis)rinvoq is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy. atopic dermatitisrinvoq is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy. ulcerative colitisrinvoq is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.  crohn’s diseaserinvoq is indicated for the treatment of adult patients with moderately to severely active crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Էստոնիա - էստոներեն - Ravimiamet

laboratoire innotech international - raud(ii)glükonaat+mangaanglükonaat+vaskglükonaat - suukaudne lahus - 5mg+0,133mg+0,07mg 1ml 10ml 20tk

Եվրոպական Միություն - էստոներեն - EMA (European Medicines Agency)

janssen cilag international nv - selexipag - hüpertensioon, kopsuvähk - antitrombootilised ained - uptravi on näidustatud pikaajaliseks pulmonaalse arteriaalse hüpertensiooni (pah) täiskasvanud patsientidel koos who funktsionaalse klassi (fc) ii-iii, kas tingituna vastunäidustatud patsientidele, kellel antagonistiga (era) ja/või fosfodiesteraasi tüüp 5 (pde5) inhibiitoritega või patsientidele, kes ei ole kandidaadid ravi saamist. efektiivsust on näidatud pah elanikkonnale, sh idiopaatiline ja pärilik pah, pah on seotud sidekoe kahjustused, ja pah seotud parandatud lihtsaid kaasasündinud südamehaigused.

Էստոնիա - էստոներեն - Ravimiamet

jubilant pharmaceuticals nv - okskarbasepiin - õhukese polümeerikattega tablett - 600mg 20tk; 600mg 90tk; 600mg 200tk; 600mg 60tk; 600mg 30tk; 600mg 100tk; 600mg 10tk; 600mg 50tk

Էստոնիա - էստոներեն - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 27,5mg 0.55ml 0.55ml 5tk; 27,5mg 0.55ml 0.55ml 12tk; 27,5mg 0.55ml 0.55ml 1tk; 27,5mg 0.55ml 0.55ml 4tk; 27,5mg 0.55ml 0.55ml 6tk; 27,5mg 0.55ml 0.55ml 2tk; 27,5mg 0.55ml 0.55ml 11tk

Էստոնիա - էստոներեն - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 30mg 0.6ml 0.6ml 2tk; 30mg 0.6ml 0.6ml 1tk; 30mg 0.6ml 0.6ml 12tk; 30mg 0.6ml 0.6ml 5tk; 30mg 0.6ml 0.6ml 4tk; 30mg 0.6ml 0.6ml 14tk; 30mg 0.6ml 0.6ml 6tk; 30mg 0.6ml 0.6ml 24tk; 30mg 0.6ml 0.6ml 10tk; 30mg 0.6ml 0.6ml 11tk

Էստոնիա - էստոներեն - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 25mg 0.5ml 0.5ml 14tk; 25mg 0.5ml 0.5ml 4tk; 25mg 0.5ml 0.5ml 6tk; 25mg 0.5ml 0.5ml 15tk; 25mg 0.5ml 0.5ml 12tk; 25mg 0.5ml 0.5ml 10tk; 25mg 0.5ml 0.5ml 2tk; 25mg 0.5ml 0.5ml 11tk; 25mg 0.5ml 0.5ml 1tk

Էստոնիա - էստոներեն - Ravimiamet

medac gesellschaft für klinische spezialpräparate mbh - metotreksaat - süstelahus pen-süstlis - 12,5mg 0.25ml 0.25ml 4tk; 12,5mg 0.25ml 0.25ml 15tk; 12,5mg 0.25ml 0.25ml 11tk; 12,5mg 0.25ml 0.25ml 5tk; 12,5mg 0.25ml 0.25ml 24tk; 12,5mg 0.25ml 0.25ml 1tk; 12,5mg 0.25ml 0.25ml 14tk; 12,5mg 0.25ml 0.25ml 10tk; 12,5mg 0.25ml 0.25ml 6tk; 12,5mg 0.25ml 0.25ml 12tk